
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AD1208
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Details : AD1208 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2025
Lead Product(s) : AD1208
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AD1208
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Stassets Investment
Deal Size : $12.3 million
Deal Type : Series B Financing
Avelos Therapeutics Announces KRW 17 Billion Series B Funding Round
Details : The funding aims to support the Avelos lead product candidate AVS1001, which is being evaluated in the early-stage clinical trials for the treatment of colon cancer and stomach cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : AD1208
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Stassets Investment
Deal Size : $12.3 million
Deal Type : Series B Financing
